131 related articles for article (PubMed ID: 11046103)
1. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.
Abelö A; Eriksson UG; Karlsson MO; Larsson H; Gabrielsson J
J Pharmacol Exp Ther; 2000 Nov; 295(2):662-9. PubMed ID: 11046103
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of gastric acid secretion by omeprazole in the dog and rat.
Larsson H; Carlsson E; Junggren U; Olbe L; Sjöstrand SE; Skånberg I; Sundell G
Gastroenterology; 1983 Oct; 85(4):900-7. PubMed ID: 6884713
[TBL] [Abstract][Full Text] [Related]
4. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs.
Kukanich B; Lascelles BD; Aman AM; Mealey KL; Papich MG
J Vet Pharmacol Ther; 2005 Oct; 28(5):461-6. PubMed ID: 16207309
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole: mode of action and effect on acid secretion in animals.
Wallmark B
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():101-6. PubMed ID: 2657278
[TBL] [Abstract][Full Text] [Related]
6. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
7. Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.
Abelö A; Holstein B; Eriksson UG; Gabrielsson J; Karlsson MO
J Pharmacokinet Pharmacodyn; 2002 Aug; 29(4):365-82. PubMed ID: 12518709
[TBL] [Abstract][Full Text] [Related]
8. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
12. L-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells.
Busque SM; Kerstetter JE; Geibel JP; Insogna K
Am J Physiol Gastrointest Liver Physiol; 2005 Oct; 289(4):G664-9. PubMed ID: 15961860
[TBL] [Abstract][Full Text] [Related]
13. Antiulcerogenic and ulcer healing effects of Solanum nigrum (L.) on experimental ulcer models: possible mechanism for the inhibition of acid formation.
Jainu M; Devi CS
J Ethnopharmacol; 2006 Mar; 104(1-2):156-63. PubMed ID: 16202548
[TBL] [Abstract][Full Text] [Related]
14. Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog.
Abelö A; Andersson M; Holmberg AA; Karlsson MO
Eur J Pharm Sci; 2006 Oct; 29(2):91-101. PubMed ID: 16831536
[TBL] [Abstract][Full Text] [Related]
15. Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.
Gedda K; Scott D; Besancon M; Lorentzon P; Sachs G
Gastroenterology; 1995 Oct; 109(4):1134-41. PubMed ID: 7557078
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral omeprazole in llamas.
Poulsen KP; Smith GW; Davis JL; Papich MG
J Vet Pharmacol Ther; 2005 Dec; 28(6):539-43. PubMed ID: 16343286
[TBL] [Abstract][Full Text] [Related]
17. The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands.
Dufner MM; Kirchhoff P; Remy C; Hafner P; Müller MK; Cheng SX; Tang LQ; Hebert SC; Geibel JP; Wagner CA
Am J Physiol Gastrointest Liver Physiol; 2005 Dec; 289(6):G1084-90. PubMed ID: 16109841
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the gastric H+,K+ -ATPase by plectrinone A, a diterpenoid isolated from Plectranthus barbatus Andrews.
Schultz C; Bossolani MP; Torres LM; Lima-Landman MT; Lapa AJ; Souccar C
J Ethnopharmacol; 2007 Apr; 111(1):1-7. PubMed ID: 17166678
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
Puchalski TA; Krzyzanski W; Blum RA; Jusko WJ
J Clin Pharmacol; 2001 Mar; 41(3):251-8. PubMed ID: 11269565
[TBL] [Abstract][Full Text] [Related]
20. Investigation into the role of cephalic stimulation of acid secretion on gastric emptying and appetite following a soup meal using the gastric acid inhibitor omeprazole.
Cecil JE; Francis J; Read NW
Appetite; 2004 Feb; 42(1):99-105. PubMed ID: 15036788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
